At the news
? NEUTRALIMPACT 2/10 8-K filed Nov 2, 2026 at 08:05 ET
Xeris Biopharma appointed Menassie M. Taddese to its Board of Directors, effective November 2, 2026, increasing board size from 8 to 9 members. Taddese, a former President of Emerging Markets at Viatris and a 20+ year Pfizer veteran, brings global commercial leadership and financial expertise. He received an initial equity award with a combined grant date fair value of approximately $450,000 and will serve on the Audit Committee.
- Board expanded from 8 to 9 members; Menassie Taddese appointed as Class II director effective November 2, 2026
- Taddese will serve on the Audit Committee and is independent under Nasdaq standards
- Initial equity award of options and RSUs with combined grant date fair value of approximately $450,000
- Taddese previously served as President, Emerging Markets at Viatris and held senior roles at Pfizer for over 20 years
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access